Article: Nicotinamide Riboside Supplementation Raises NAD+ and Lowers Alzheimer's-Associated Biomarkers: Clinical Findings

Dec 14, 2022 Clinical Neurological Health

Nicotinamide Riboside Supplementation Raises NAD+ and Lowers Alzheimer's-Associated Biomarkers: Clinical Findings

Objectives

To evaluate if NR could augment neuronal NAD+ levels and impact markers of neurodegeneration and insulin-signaling in plasma-derived human neuronal extracellular vesicles (NEVs).

Journal

Aging Cell

Key Outcomes

NR supplementation significantly increased NAD+ in plasma derived human neuronal extracellular vesicles (NEVs), suggesting an increase in neuronal NAD+ levels.
In NEVs, NR also decreased levels of Aβ42, an Alzheimer's disease biomarker, as well as biomarkers pJNK and pERK1/2, which are involved in insulin resistance and neuroinflammatory pathways.

Duration

6 weeks

Dose

1000 mg

Study Design

Randomized, double-blind, placebo-controlled, crossover study in 22 healthy, middle-aged and older men and women

See Published Study

Metabolic Health

Combination of Metabolic Cofactors and Nicotinamide Riboside Reduces Obesity and Insulin Resistance: Preclinical Findings

SynopsisObesity is a global health problem marked by excessive fat that often leads to metabolic issues like insulin resistance, high blood pressure, abnormal cholesterol levels, and metabolic synd...

Alzheimer's Disease

Combined Metabolic Activators Improve Mitochondrial Metabolism in Alzheimer's and Parkinson's Disease: Preclinical Findings

Synopsis Neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD) are linked to metabolic problems, including mitochondrial dysfunction. This study analyzed human brai...